Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 2,366 | 28% |
| 2020 | 43 | 1,921 | 30% |
| 2021 | 54 |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 30% of the cases CMS names in Massachusetts; 43 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 138 | 7,854+9.3%/yr | +9.3%/yr | 3.6 | 0% | 15,300 in 2030+12%/yr |
| Pennsylvania | 131 | 5,803 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 90 | 4,351−1.6%/yr | −1.6%/yr | 4.71.0× | 0% | 4,910 in 2030+2%/yr |
| LAA occlusion & loop recorders |
EP ablation in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
| 2024 |
| 4,222 |
| 39% |
| 2025 est. | ≈ 5,830 | – |
| 2026 est. | ≈ 6,500 | – |
| 2,668 |
| 32% |
| 2022 | 56 | 2,877 | 35% |
| 2023 | 64 | 3,430 | 38% |
| 2024 | 73 | 4,222 | 39% |
| 2025 from claims | – | 5,834 5,354–6,173 | 40% |
| 2026 forecast | – | 6,498 5,717–7,498 | 39% |
| 2027 forecast | – | 7,157 6,118–8,529 | 40% |
| 2028 forecast | – | 7,883 6,577–9,652 | 40% |
| 2029 forecast | – | 8,682 7,091–10,888 | 40% |
| 2030 forecast | – | 9,562 7,660–12,253 | 40% |
In 2025, 17% inpatient hospital, 83% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +11%/yr |
| 3.5 |
| 0% |
| 11,400 in 2030+12%/yr |
| New Jersey | 61 | 3,055+5.7%/yr | +5.7%/yr | 2.5 | 0% | 5,460 in 2030+10%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.3 | 0% | 1,750 in 2030+11%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.3 | 0% | 1,590 in 2030+18%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.1 | 0% | 870 in 2030+14%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.4 | 0% | 920 in 2030+16%/yr |
| Vermont | 6 | 187+11%/yr | +11%/yr | 1.5 | 0% | 630 in 2030+22%/yr |
| 67 |
| 2,548+8.4%/yr |
| +8.4%/yr |
| 2.40.7× |
| 8% |
| 4,890 in 2030+11%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 42% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 7 companies reported engagement with Massachusetts’s surgeons worth $867K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.